AMAG Pharmaceuticals Appoints New Members to Board of Directors
April 12 2019 - 8:00AM
AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced the
election of two new members to its Board of Directors—Anne
Phillips, M.D., senior vice president, clinical development,
medical and regulatory affairs for Novo Nordisk, Inc. and Kathrine
O'Brien, former vice president and general manager, skin and
marketing services for Unilever PLC. In addition, after serving on
AMAG’s board for nearly 10 years, Lesley Russell, M.D. will not be
a nominee for election at the Company's 2019 annual meeting of
stockholders.
“We are pleased to welcome Dr. Phillips and Ms. O’Brien to
AMAG’s board,” said Gino Santini, chairman of the board of AMAG.
“As AMAG continues to invest and focus on the development and
commercialization of novel pharmaceutical products that address
unmet medical needs, the deep experience and expertise that Dr.
Phillips and Ms. O’Brien each bring will be invaluable to AMAG. On
behalf of the board, we also want to thank Dr. Russell for her
valuable perspective and support as the company transforms its
focus on more development stage opportunities.”
Dr. Phillips’ extensive clinical development background and Ms.
O’Brien’s broad direct-to-consumer digital marketing experience
will help to support and guide AMAG’s growing pipeline and its
commercialized women’s health products.
Dr. Phillips brings more than 25 years of drug development,
clinical operations, medical and regulatory experience to the AMAG
board. In her current role at Novo Nordisk, Dr. Phillips is
responsible for the clinical development of the Novo Nordisk
portfolio of compounds, including product lifecycle initiatives.
She is also a director on the board of Trevana, Inc. (NASDAQ:TRVN).
Dr. Phillips is a Fellow of The Royal College of Physicians and
Surgeons of Canada, and earned a medical degree from the University
of Toronto and received a Bachelor of Sciences from the University
of Western Ontario.
Ms. O’Brien is an experienced consumer marketing executive with
a focus on women’s personal care products. She joins the board with
a deep understanding and knowledge of consumer and digital
engagement. In her most recent role at Unilever, Ms. O’Brien
initiated, implemented and led direct-to-consumer digital marketing
strategies for the skin care business. She is also a director
on the board of Tabala Rasa Healthcare, Inc.
(NASDAQ:TRHC). Ms. O’Brien holds a Bachelor of Arts in
economics from Boston College and a Master of Business
Administration from Columbia University.
About AMAGAMAG is a
pharmaceutical company focused on bringing innovative products to
patients with unmet medical needs. The company does this by
leveraging its development and commercial expertise to invest in
and grow its pharmaceutical products across a range of therapeutic
areas, including women’s health. For additional company
information, please visit www.amagpharma.com.
Forward-Looking Statements This
press release contains forward-looking information about AMAG
Pharmaceuticals, Inc. within the meaning of the Private
Securities Litigation Reform Act of 1995 and other federal
securities laws. Any statements contained herein which do not
describe historical facts, including, among others, Dr. Phillips’
and Ms. O’Brien’s expected contributions to AMAG’s board and AMAG’s
beliefs that Dr. Phillips’ and Ms. O’Brien’s experience will help
to support and guide AMAG’s growing pipeline and its commercialized
women’s health products are forward-looking statements which
involve risks and uncertainties that could cause actual results to
differ materially from those discussed in such forward-looking
statements. Such risks and uncertainties include, among others,
those risks identified in AMAG’s filings with the U.S.
Securities and Exchange Commission (the SEC), including
its Annual Report on Form 10‐K for the year ended December 31,
2018, and subsequent filings with the SEC, which are available
at the SEC’s website at www.sec.gov. Any such risks and
uncertainties could materially and adversely affect AMAG’s results
of operations, its profitability and its cash flows, which would,
in turn, have a significant and adverse impact on AMAG’s stock
price. AMAG cautions you not to place undue reliance on any
forward‐looking statements, which speak only as of the date they
are made.
AMAG disclaims any obligation to publicly update or revise any
such statements to reflect any change in expectations or in events,
conditions or circumstances on which any such statements may be
based, or that may affect the likelihood that actual results will
differ from those set forth in the forward‐looking statements.
AMAG Pharmaceuticals® is a registered trademark of AMAG
Pharmaceuticals, Inc.
AMAG Pharmaceuticals Contacts: Investors: Linda
Lennox908-627-3424
Media: Sarah Connors 781-296-0722
AMAG Pharmaceuticals (NASDAQ:AMAG)
Historical Stock Chart
From Aug 2024 to Sep 2024
AMAG Pharmaceuticals (NASDAQ:AMAG)
Historical Stock Chart
From Sep 2023 to Sep 2024